News
OMER
2.050
-2.38%
-0.050
Why Canoo Shares Are Trading Higher By Over 12%? Here Are 32 Stocks Moving In Friday's Mid-Day Session
Benzinga · 11/25 17:01
US Stocks Mixed On Black Friday; Dow Rises Over 100 Points
Benzinga · 11/25 15:06
BRIEF-Omeros Corp May Offer And Sell Shares Of Common Stock From Time To Time Of Up To $150.0 Million Through Cantor
Reuters · 11/18 11:26
BRIEF-Omeros Corp Files For Mixed Shelf Of Up To $300 Million - SEC Filing
Reuters · 11/09 22:50
Omeros Q3 EPS $(0.28) Beats $(0.52) Estimate
Benzinga · 11/09 21:12
BRIEF-Omeros Corporation Reports Third Quarter 2022 Financial Results
Reuters · 11/09 21:04
Omeros GAAP EPS of -$0.28 beats by $0.28
Seekingalpha · 11/09 21:03
--BofA Securities Downgrades Omeros to Underperform Rating From Neutral, Price Target is $3
--BofA Securities Downgrades Omeros to Underperform Rating From Neutral, Price Target is $3
MT Newswires · 11/09 09:03
Omeros Q3 2022 Earnings Preview
Seekingalpha · 11/08 22:35
B of A Securities Downgrades Omeros to Underperform, Announces $3 Price Target
Benzinga · 11/08 18:44
Omeros downgraded at Bank of America after FDA snub for narsoplimab appeal
Seekingalpha · 11/08 17:16
BRIEF-Omeros Corp Receives Decision From FDA On Formal Dispute Resolution Request For Narsoplimab
Reuters · 11/08 15:32
Preview: Omeros's Earnings
Benzinga · 11/08 14:12
Omeros appeal of FDA Complete Response Letter on narsoplimab denied; shared down 7%
Seekingalpha · 11/08 13:53
Omeros Corporation Receives Decision From FDA On Formal Dispute Resolution Request For Narsoplimab
Benzinga · 11/08 13:34
Omeros Says FDA Rejects Appeal of Complete Response Letter on its BLA for Narsoplimab to Treat Thrombotic Microangiopathy
Omeros Says FDA Rejects Appeal of Complete Response Letter on its BLA for Narsoplimab to Treat Thrombotic Microangiopathy
MT Newswires · 11/08 11:17
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022
SEATTLE, November 04, 2022--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter financial results for the period ended September 30, 2022, on Wednesday, November 9, 2022, after the market closes. Omeros manageme...
Business Wire · 11/04 13:00
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
SEATTLE, November 03, 2022--Omeros Corporation (Nasdaq: OMER) today announced that two presentations pertaining to Omeros’ investigational complement inhibitors will be featured at the upcoming 64th American Society of Hematology (ASH) Annual Meeting, whic...
Business Wire · 11/03 13:00
BIGC, OMER and CARG are among after hour
Seekingalpha · 10/25 22:00
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 10/25 21:41
More
Webull provides a variety of real-time OMER stock news. You can receive the latest news about Omeros through multiple platforms. This information may help you make smarter investment decisions.
About OMER
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic diseases, including complement-mediated diseases and cancers related to dysfunction of the immune system, as well as addictive and compulsive disorders. Its lead lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome, and COVID-19. OMS906, its inhibitor of MASP-3, an activator of the alternative pathway of complement, is initiating a Phase I b clinical program in paroxysmal nocturnal hemoglobinuria (PNH).